| home | faq | contact us | mailing list |
NIC5-15
The Development of NIC5-15 in the Treatment of Alzheimer's Disease
| Status: | Active and Recruiting |
| Eligible Population(s): | Alzheimer's Disease |
| GCO Number: | 05-0173 IRB approved through 06/30/2009 |
| Principal Investigator: | Hillel Grossman, MD |
| Study Coordinator: | George Marzloff |
We are seeking patients with Alzheimer's disease to participate in a research study on a dietary supplement that may help improve memory. Some study participants will receive the supplement and some will receive a placebo (sugar pill). This supplement has anti-diabetic effects in people and has been shown to improve memory in laboratory animals. It also reduces the production of amyloid, a major ingredient in Alzheimer's plaques, in test-tube conditions.
The purpose of the study is to determine whether this product is safe and effective in treating Alzheimer's disease. This natural product (called NIC5-15) is a dietary supplement found in many foods, including soybeans. Participation in the study will last seven weeks, and includes memory testing, neurological exams and blood tests.
For more information, please contact George Marzloff at Mount Sinai's Alzheimer's Disease Research Center, 212-241-1514.
For more information
If you would like a coordinator to contact you regarding NIC5-15, please complete the form below.